Detalles de la búsqueda
1.
Health-related quality of life in patients with generalized pustular psoriasis: A systematic literature review.
J Eur Acad Dermatol Venereol
; 38(2): 265-280, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37750484
2.
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.
Br J Dermatol
; 184(4): 640-651, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32531798
3.
Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
Br J Dermatol
; 185(6): 1124-1134, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33913511
4.
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).
Br J Dermatol
; 184(4): 652-662, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32652544
5.
Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial.
Br J Dermatol
; 182(4): 889-899, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31286480
6.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Br J Dermatol
; 182(6): 1348-1358, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31887225
7.
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.
Br J Dermatol
; 180(1): 67-75, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30188571
8.
Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.
Br J Dermatol
; 181(3): 483-491, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30724351
9.
Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.
J Eur Acad Dermatol Venereol
; 33(3): 546-552, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30242918
10.
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Br J Dermatol
; 179(2): 320-328, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29488226
11.
A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process.
Br J Dermatol
; 179(3): 642-650, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29654696
12.
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.
Br J Dermatol
; 179(4): 844-852, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29747232
13.
Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II.
Br J Dermatol
; 178(3): 715-721, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29080368
14.
Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.
J Eur Acad Dermatol Venereol
; 32(8): 1305-1313, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29512200
15.
Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
J Eur Acad Dermatol Venereol
; 31(3): 477-482, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27910156
16.
Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
J Eur Acad Dermatol Venereol
; 31(4): 679-685, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27696577
17.
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
Br J Dermatol
; 175(2): 273-86, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26914406
18.
Older adults on systemic treatment for psoriasis and risk of infection: a propensity score-matched population-based study.
Br J Dermatol
; 183(3): 564-566, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32159850
19.
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
Br J Dermatol
; 172(2): 484-93, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25132411
20.
Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo.
Br J Dermatol
; 173(3): 641-50, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26149498